Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 70 years
- People with a Body Mass Index (BMI) between 30 and 40 (a measure of weight relative to height that falls in the obese range)
- People willing and able to understand and follow the study protocol
- People who have been diagnosed with Crohn's disease or Ulcerative Colitis at least 3 months before the screening visit
- People whose IBD (inflammatory bowel disease) has been in remission (inactive, well-controlled disease) for at least 6 months before screening, without the use of steroid medications during that time — as confirmed by specific disease activity scores used by the medical team
- People who have been on a stable, unchanged treatment dose for their IBD for at least 8 weeks before the start of the study
Who may not be able to join:
- People with an active Helicobacter pylori infection causing damage (erosions or ulcers) to the stomach or the first part of the small intestine
- People with a structural or movement disorder affecting the stomach or oesophagus (food pipe)
- People who have previously had weight-loss (bariatric) surgery, or any other surgery that has changed the shape of the oesophagus, stomach, or upper small intestine
- People with an ongoing or active cancer diagnosis within the last 5 years
- People who have had a heart attack in the past 6 months, or who have severe heart failure (classified as Class III or IV by medical criteria)
- People with drug or alcohol dependency
- People with patterns of bulimia or binge eating
- People with thyroid disease that is not well controlled
- People who are pregnant or breastfeeding
- People with psychiatric conditions, cooperation difficulties, or a history of low compliance that the medical team considers a barrier to participation
- People with liver cirrhosis at any stage, or with a specific liver function score above 15 (confirm with trial site)
- People with severely reduced kidney function, based on a specific kidney filtration measurement below a set threshold
- People currently participating in another clinical study, or who have participated in a study involving an experimental drug within the past 30 days (or within 5 times the drug's clearance period, whichever is longer)
- People whose IBD is currently active, as determined by specific disease activity scores or by current use of systemic steroids to manage disease symptoms
- People with any other health condition that the trial investigator judges could put them at risk from the treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lucrezia Laterza, PI, Fondazione Policlinico A. Gemelli IRCCS, Rome
Phone: +390630156876
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility Assessment Based on Completion Rate of ESG Procedure Without Complications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.